Financials data is unavailable for this security.
View more
Year on year Harmony Biosciences Holdings Inc had net income fall -28.99% from 181.47m to 128.85m despite a 32.93% increase in revenues from 437.86m to 582.02m. An increase in the cost of goods sold as a percentage of sales from 19.07% to 20.83% was a component in the falling net income despite rising revenues.
Gross margin | 79.41% |
---|---|
Net profit margin | 17.53% |
Operating margin | 25.66% |
Return on assets | 14.21% |
---|---|
Return on equity | 22.46% |
Return on investment | 16.68% |
More ▼
Cash flow in USDView more
In 2023, Harmony Biosciences Holdings Inc increased its cash reserves by 27.56%, or 67.40m. The company earned 219.39m from its operations for a Cash Flow Margin of 37.69%. In addition the company used 46.44m on investing activities and also paid 105.55m in financing cash flows.
Cash flow per share | 2.38 |
---|---|
Price/Cash flow per share | 15.90 |
Book value per share | 9.48 |
---|---|
Tangible book value per share | 7.27 |
More ▼
Balance sheet in USDView more
Current ratio | 3.13 |
---|---|
Quick ratio | 3.09 |
Total debt/total equity | 0.3461 |
---|---|
Total debt/total capital | 0.2571 |
More ▼